Overview

  • Product nameAnti-APC antibody [ALi 12-28]
    See all APC primary antibodies
  • Description
    Mouse monoclonal [ALi 12-28] to APC
  • Tested applicationsSuitable for: ICC/IF, Flow Cyt, WB, IHC-Frmore details
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse
  • Immunogen

    Amino acids 1-433 N-terminal fragment of human APC (Adenomutons Polyposis Coli gene Chr 5q) fused to maltose binding protein.

  • EpitopeALI-12-28 was epitope mapped by differential in vitro expression of the N-terminal region of the APC gene by using the protein truncation test and was found to bind to APC in the region between nucleotides 135 and 422 (exons 2-3) (Efstathiou et al.).

Properties

Applications

Our Abpromise guarantee covers the use of ab58 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 23658710
Flow Cyt Use 1µg for 106 cells.
WB Use at an assay dependent concentration. This antibody has been used routinely for Western blotting on colon cell line HCT116, SW480 and SW837 extracts.
IHC-Fr Use at an assay dependent concentration.

Target

  • FunctionTumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization.
  • Tissue specificityExpressed in a variety of tissues.
  • Involvement in diseaseDefects in APC are a cause of familial adenomatous polyposis (FAP) [MIM:175100]; which includes also Gardner syndrome (GS). FAP and GS contribute to tumor development in patients with uninherited forms of colorectal cancer. FAP is characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.
    Defects in APC are a cause of hereditary desmoid disease (HDD) [MIM:135290]; also known as familial infiltrative fibromatosis (FIF). HDD is an autosomal dominant trait with 100% penetrance and possible variable expression among affected relatives. HDD patients show multifocal fibromatosis of the paraspinal muscles, breast, occiput, arms, lower ribs, abdominal wall, and mesentery. Desmoid tumors appears also as a complication of familial adenomatous polyposis.
    Defects in APC are a cause of medulloblastoma (MDB) [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Although the majority of medulloblastomas occur sporadically, some manifest within familial cancer syndromes such as Turcot syndrome and basal cell nevus syndrome (Gorlin syndrome).
    Defects in APC are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
    Defects in APC are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
    Defects in APC are a cause of hepatocellular carcinoma (HCC) [MIM:114550]. This defect includes also the disease entity termed hepatoblastoma.
  • Sequence similaritiesBelongs to the adenomatous polyposis coli (APC) family.
    Contains 7 ARM repeats.
  • DomainThe microtubule tip localization signal (MtLS) motif; mediates interaction with MAPRE1 and targeting to the growing microtubule plus ends.
  • Post-translational
    modifications
    Phosphorylated by GSK3B.
    Ubiquitinated, leading to its degradation by the proteasome. Ubiquitination is facilitated by Axin. Deubiquitinated by ZRANB1/TRABID.
  • Cellular localizationCell junction > adherens junction. Cytoplasm > cytoskeleton. Cell projection > lamellipodium. Cell projection > ruffle membrane. Cytoplasm. Cell membrane. Associated with the microtubule network at the growing distal tip of microtubules. Accumulates in the lamellipodium and ruffle membrane in response to hepatocyte growth factor (HGF) treatment. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosophorylated form to the cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Adenomatous Polyposis Coli antibody
    • Adenomatous polyposis coli protein antibody
    • Apc antibody
    • APC_HUMAN antibody
    • CC1 antibody
    • Deleted in polyposis 2.5 antibody
    • DP2 antibody
    • DP2.5 antibody
    • DP3 antibody
    • FAP antibody
    • FPC antibody
    • GS antibody
    • Protein APC antibody
    see all

Anti-APC antibody [ALi 12-28] images

  • Overlay histogram showing HCT116 cells stained with ab58 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab58, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

References for Anti-APC antibody [ALi 12-28] (ab58)

This product has been referenced in:
  • Yamulla RJ  et al. Testing models of the APC tumor suppressor/ß-catenin interaction reshapes our view of the destruction complex in Wnt signaling. Genetics 197:1285-302 (2014). WB ; Human . Read more (PubMed: 24931405) »
  • Boehlke C  et al. Kif3a guides microtubular dynamics, migration and lumen formation of MDCK cells. PLoS One 8:e62165 (2013). ICC/IF . Read more (PubMed: 23658710) »

See all 12 Publications for this product

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (mammary tumor)
Specification mammary tumor
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Sodium Citrate
Permeabilization No
Blocking step GOAT BLOCK = 10mM Tris pH 7.4, 100mM MgCl2, 0.5% Tween, 1% BSA, 5% normal goat serum (IN WATER) as blocking agent for 20 minute(s) · Concentration: 100% · Temperature: 4°C
Username

Abcam user community

Verified customer

Submitted Mar 06 2013

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Colon Tumor and Ameloblastoma)
Specification Colon Tumor and Ameloblastoma
Fixative 10% buffered formalin
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10mM Citrate Buffer
Permeabilization No
Blocking step (agent) for 30 minute(s) · Concentration: 10% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Dec 03 2010

Thank you for your enquiry. I have enquired with the originator of ab58 and unfortunately, we do not have this information. If you have any additional questions, please let us know.

Thank you for your enquiry. As can be seen in the following publication, this antibody blots wildtype APC at 310kDa. Efstathiou JA et al. 1998. Proc. Natl. Acad. Sci. USA. 95(6):3122-719. I would recommend starting at a dilution of 1:500/1:1000 and...

Read More

I assume that you are refering to our general FACs protocol where point 2. advises 2. Add 0.1-10 µg/ml of the primary antibody. Dilutions, if necessary, should be made in 3% BSA/PBS Here we mean 3% BSA in 1 X PBS

Try this antibody at 1:100 as a starting point and then adjust the dilution according to the results obtained. The actual concentration to use an antibody at is always best assessed by the individual laboratory.

There is a misprint (error) on the tube label - the concentration is actually 1mg/ml. For Western blotting, it is routinely used at 1/1000 dilution although you may have to titrate to optimise for your specific conditions.

This antibody has not been tested on paraffin sections.

Thank you for your useful comments. We have updated the datasheet to include the full name of the antigen, to avoid confusion with other proteins referred to as APC.

Routinely it is used at 1ug per ml although you may have to titrate to find the optimal dilution for your experiment.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"